We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
Read MoreHide Full Article
Key Takeaways
Acadia generated $576 million in first-half 2026 revenues, up 13%, and raised its 2026 guidance.
Nuplazid H1 sales rose 7% to $350.1 million, with 34-mg capsule patent protection until February 2038.
Daybue H1 sales jumped 25% to $226 million, fueled by STIX uptake and EU approval for Rett syndrome treatment.
Acadia Pharmaceuticals (ACAD - Free Report) relies on its two marketed drugs, Nuplazid (pimavanserin) and Daybue (trofinetide), to sustain growth as it advances its central nervous system (CNS) and rare disease pipeline. The company generated $576 million in total revenues in the first half of 2026, up 13% year over year, reflecting continued demand for both products. Acadia raised its full-year 2026 revenue guidance to $1.24-$1.30 billion following strong second-quarter performance, highlighting the importance of sustaining prescription growth and expanding access to its marketed therapies.
Nuplazid remains Acadia’s established revenue anchor. Approved in the United States for hallucinations and delusions associated with Parkinson’s disease psychosis, the drug generated $350.1 million in first-half 2026 sales, up 7% year over year, driven primarily by higher unit sales. Its expanded sales force and increasing new-patient prescriptions could support further growth. Favorable patent rulings and settlement agreements protect Nuplazid’s 34-mg capsule from generic entry until February 2038, subject to earlier-entry provisions. A separate dispute over Zydus’ proposed 34-mg tablet and alleged breach of the settlement agreement is scheduled for trial in November 2026.
Daybue is providing a faster-growing second revenue stream. First-half 2026 sales rose 25% year over year to $226 million, supported by rising demand and uptake of Daybue STIX, a powder formulation that became broadly available in the United States in April 2026. By the end of June, around 40% of U.S. patients receiving Daybue were using STIX, highlighting early adoption of the new formulation. In August, the European Commission also authorized Daybu (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and children aged five years and older, creating an additional opportunity for international expansion as pricing and reimbursement discussions progress.
Acadia expects Nuplazid to generate $760-$790 million in full-year 2026 sales, while global Daybue sales are forecast at $480-$510 million. Nuplazid provides an established commercial base, while Daybue’s faster growth and expanding geographic reach offer diversification. Continued prescription growth, successful commercialization of STIX and European market access will be important to meeting these targets and sustaining the company’s growth trajectory.
ACAD Faces Competition Across CNS & Rare Neurological Diseases
Acadia faces competition across CNS and rare neurological disorders as rivals expand their marketed therapies and develop new treatments, including Axsome Therapeutics (AXSM - Free Report) and Neurogene (NGNE - Free Report) .
Axsome has a diversified CNS portfolio, led by Auvelity for major depressive disorder and Alzheimer’s-related agitation, alongside Sunosi for excessive daytime sleepiness and Symbravo for acute migraine. Its products generated $409.6 million in net revenues in the first half of 2026, up 51% year over year, driven primarily by Auvelity sales growth. Axsome is also advancing pipeline candidates for narcolepsy and attention-deficit/hyperactivity disorder. Although its marketed drugs do not directly compete with ACAD’s Nuplazid or Daybue, its expanding portfolio highlights growing competition across CNS disorders.
Neurogene represents a potential future competitor for Acadia in Rett syndrome. Its investigational, one-time gene therapy NGN-401 is currently being evaluated in a registrational phase III Embolden study in females aged three years and older with Rett syndrome. Neurogene has completed dosing in 25 patients, with top-line results expected in the second half of 2027. In June 2026, NGNE reported long-term data from a phase I/II study of the candidate showing clinical improvement and gains in at least one developmental milestone in all 10 patients with Rett syndrome. NGN-401’s successful development could introduce a different treatment approach for Rett syndrome.
Year to date, ACAD shares have lost 27.3% against the industry’s 2.6% growth. Acadia has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
ACAD Stock Underperforms the Industry, Sector & the S&P 500
Image Source: Zacks Investment Research
Acadia is trading at a discount to the industry, as seen in the chart below. Going by the price/book value ratio, the company’s shares currently trade at 2.56, which is less than 3.87 for the industry. The stock is trading significantly below its five-year mean of 5.53.
ACAD Stock Valuation
Image Source: Zacks Investment Research
Earnings estimates for 2026 have increased from 59 cents to 64 cents per share over the past 60 days. During the same time frame, ACAD’s 2027 earnings per share estimates have improved from 95 cents to 98 cents.
View the Zacks #1 Rank List
Image: Bigstock
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
Key Takeaways
Acadia Pharmaceuticals (ACAD - Free Report) relies on its two marketed drugs, Nuplazid (pimavanserin) and Daybue (trofinetide), to sustain growth as it advances its central nervous system (CNS) and rare disease pipeline. The company generated $576 million in total revenues in the first half of 2026, up 13% year over year, reflecting continued demand for both products. Acadia raised its full-year 2026 revenue guidance to $1.24-$1.30 billion following strong second-quarter performance, highlighting the importance of sustaining prescription growth and expanding access to its marketed therapies.
Nuplazid remains Acadia’s established revenue anchor. Approved in the United States for hallucinations and delusions associated with Parkinson’s disease psychosis, the drug generated $350.1 million in first-half 2026 sales, up 7% year over year, driven primarily by higher unit sales. Its expanded sales force and increasing new-patient prescriptions could support further growth. Favorable patent rulings and settlement agreements protect Nuplazid’s 34-mg capsule from generic entry until February 2038, subject to earlier-entry provisions. A separate dispute over Zydus’ proposed 34-mg tablet and alleged breach of the settlement agreement is scheduled for trial in November 2026.
Daybue is providing a faster-growing second revenue stream. First-half 2026 sales rose 25% year over year to $226 million, supported by rising demand and uptake of Daybue STIX, a powder formulation that became broadly available in the United States in April 2026. By the end of June, around 40% of U.S. patients receiving Daybue were using STIX, highlighting early adoption of the new formulation. In August, the European Commission also authorized Daybu (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and children aged five years and older, creating an additional opportunity for international expansion as pricing and reimbursement discussions progress.
Acadia expects Nuplazid to generate $760-$790 million in full-year 2026 sales, while global Daybue sales are forecast at $480-$510 million. Nuplazid provides an established commercial base, while Daybue’s faster growth and expanding geographic reach offer diversification. Continued prescription growth, successful commercialization of STIX and European market access will be important to meeting these targets and sustaining the company’s growth trajectory.
ACAD Faces Competition Across CNS & Rare Neurological Diseases
Acadia faces competition across CNS and rare neurological disorders as rivals expand their marketed therapies and develop new treatments, including Axsome Therapeutics (AXSM - Free Report) and Neurogene (NGNE - Free Report) .
Axsome has a diversified CNS portfolio, led by Auvelity for major depressive disorder and Alzheimer’s-related agitation, alongside Sunosi for excessive daytime sleepiness and Symbravo for acute migraine. Its products generated $409.6 million in net revenues in the first half of 2026, up 51% year over year, driven primarily by Auvelity sales growth. Axsome is also advancing pipeline candidates for narcolepsy and attention-deficit/hyperactivity disorder. Although its marketed drugs do not directly compete with ACAD’s Nuplazid or Daybue, its expanding portfolio highlights growing competition across CNS disorders.
Neurogene represents a potential future competitor for Acadia in Rett syndrome. Its investigational, one-time gene therapy NGN-401 is currently being evaluated in a registrational phase III Embolden study in females aged three years and older with Rett syndrome. Neurogene has completed dosing in 25 patients, with top-line results expected in the second half of 2027. In June 2026, NGNE reported long-term data from a phase I/II study of the candidate showing clinical improvement and gains in at least one developmental milestone in all 10 patients with Rett syndrome. NGN-401’s successful development could introduce a different treatment approach for Rett syndrome.
ACAD’s Stock Price, Valuation & Estimate Movements
Year to date, ACAD shares have lost 27.3% against the industry’s 2.6% growth. Acadia has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
ACAD Stock Underperforms the Industry, Sector & the S&P 500
Acadia is trading at a discount to the industry, as seen in the chart below. Going by the price/book value ratio, the company’s shares currently trade at 2.56, which is less than 3.87 for the industry. The stock is trading significantly below its five-year mean of 5.53.
ACAD Stock Valuation
Earnings estimates for 2026 have increased from 59 cents to 64 cents per share over the past 60 days. During the same time frame, ACAD’s 2027 earnings per share estimates have improved from 95 cents to 98 cents.
ACAD Estimate Movement
Acadia currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.